Osteocytes in the pathogenesis of osteoporosis

Geriatrics and Gerontology International

Volumn 8, Issue 4, 2008, Pages 213-217

  Ikeda, Kyoji ^a  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Aging; Mechanotransduction; Microdamage; Osteocyte; Osteoporosis

Indexed keywords

ANIMAL; HUMAN; MOUSE; OSTEOCYTE; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; TRANSGENIC MOUSE;

ANIMALS; HUMANS; MICE; MICE, TRANSGENIC; OSTEOCYTES; OSTEOPOROSIS;

EID: 56649114147     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2008.00481.x     Document Type: Review

References (32)

1. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332: 305-311.
2. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996; 11: 1043-1051.
3. Ducy P, Schinke T, Karsenty G. The osteoblast: A sophisticated fibroblast under central surveillance. Science 2000; 289: 1501-1504.
4. Takayanagi H, Ogasawara K, Hida S et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000; 408: 600-605.
5. Burger EH, Klein-Nulend J. Mechanotransduction in bone -role of the lacuno-canalicular network. FASEB J 1999; 13(Suppl.): S101-S112.
6. Ehrlich PJ, Lanyon LE. Mechanical strain and bone cell function: A review. Osteoporos Int 2002; 13: 688-700.
7. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006; 354: 2250-2261.
8. Raisz LG. Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest 2005; 115: 3318-3325.
9. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002; 359: 1841-1850.
10. Riggs BL, Melton LJ III. Involutional osteoporosis. N Engl J Med 1986; 314: 1676-1686.
11. Aarden EM, Burger EH, Nijweide PJ. Function of osteocytes in bone. J Cell Biochem 1994; 55: 287-299.
12. Franz-Odendaal TA, Hall BK, Witten PE. Buried alive: How osteoblasts become osteocytes. Dev Dyn 2006; 235: 176-190.
13. Kato Y, Windle JJ, Koop BA, Mundy GR, Bonewald LF. Establishment of an osteocyte-like cell line, MLO-Y4. J Bone Miner Res 1997; 12: 2014-2023.
14. Saito M, Iwawaki T, Taya C etal. Diphtheria toxin receptor-mediated conditional and targeted cell ablation in transgenic mice. Nat Biotechnol 2001; 19: 746-750.
15. Tatsumi S, Ishii K, Amizuka N et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 2007; 5: 464-475.
16. Sissons HA, O'Connor P. Quantitative histology of osteocyte lacunae in normal human cortical bone. Calcif Tissue Res 1977; 22(Suppl.): 530-533.
17. Toyosawa S, Shintani S, Fujiwara T et al. Dentin matrix protein 1 is predominantly expressed in chicken and rat osteocytes but not in osteoblasts. J Bone Miner Res 2001; 16: 2017-2026.
18. Lorenz-Depiereux B, Bastepe M, Benet-Pages A et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006; 38: 1248-1250.
19. Feng JQ, Ward LM, Liu S et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006; 38: 1310-1315.
20. van Bezooijen RL, Roelen BA, Visser A et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004; 199: 805-814.
21. Winkler DG, Sutherland MK, Geoghegan JC et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003; 22: 6267-6276.
22. George A, Sabsay B, Simonian PA, Veis A. Characterization of a novel dentin matrix acidic phosphoprotein. Implications for induction of biomineralization. J Biol Chem 1993; 268: 12624-12630.
23. Qiu S, Rao DS, Palnitkar S, Parfitt AM. Reduced iliac cancellous osteocyte density in patients with osteoporotic vertebral fracture. J Bone Miner Res 2003; 18: 1657-1663.
24. Tomkinson A, Reeve J, Shaw RW, Noble BS. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab 1997; 82: 3128-3135.
25. Tomkinson A, Gevers EF, Wit JM, Reeve J, Noble BS. The role of estrogen in the control of rat osteocyte apoptosis. J Bone Miner Res 1998; 13: 1243-1250.
26. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102: 274-282.
27. Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 2000; 85: 2907-2912.
28. O'Brien CA, Jia D, Plotkin LI et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004; 145: 1835-1841.
29. Verborgt O, Gibson GJ, Schaffler MB. Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. J Bone Miner Res 2000; 15: 60-67.
30. Martin RB. Fatigue microdamage as an essential element of bone mechanics and biology. Calcif Tissue Int 2003; 73: 101-107.
31. Hazenberg JG, Taylor D, Lee TC. The role of osteocytes and bone microstructure in preventing osteoporotic fractures. Osteoporos Int 2007; 18: 1-8.
32. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999; 104: 439-446.